Oncology Reviews

, Volume 2, Issue 4, pp 250–258 | Cite as

Historical perspective and advances in the treatment of multiple myeloma

Review
  • 23 Downloads

Abstract

Corticosteroids and melphalan were used for decades to treat multiple myeloma. Combination chemotherapy has been extensively studied with similar overall survival rates to melphalan and prednisone. In the last decade, the development of new agents has progressed significantly. Thalidomide and its newer derivatives lenalidomide, bortezomib, and pegylated liposomal doxorubicin have drastically revolutionized treatment approaches. As a result, numerous clinical trials have yielded exciting treatment strategies resulting in therapeutic advances, and improved responses and overall survival of patients. This review summarizes the international uniform response criteria for multiple myeloma and gives a historical perspective on previous therapies with updates on the newest available treatments.

Keywords

Multiple myeloma Chemotherapy Advances in treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Durie BG, Harousseau JL, Miguel JS et al (2006) International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473PubMedCrossRefGoogle Scholar
  2. 2.
    Bergsagel DE, Sprague CC, Austin C et al (1962) Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard (NC-8806). Cancer Chemotherapy Rep 21:87Google Scholar
  3. 3.
    Oken MM, Harrington DP, Abramson N et al (1997) Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 79:1561–1567PubMedCrossRefGoogle Scholar
  4. 4.
    [No Authors Listed] (1998) Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832–3842Google Scholar
  5. 5.
    Hernández JM, García-Sanz R, Golvano E et al (2004) Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 127:159–164PubMedCrossRefGoogle Scholar
  6. 6.
    Barlogie B, Drewinko B, Johnston DA et al (1976) The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line. Cancer Res 36:1975–1979PubMedGoogle Scholar
  7. 7.
    Barlogie B, Smith L, Alexanian R et al (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353–1356PubMedGoogle Scholar
  8. 8.
    Alexanian R, Barlogie B (1990) New treatment strategies for multiple myeloma. Am J Hematol 35:194–198PubMedCrossRefGoogle Scholar
  9. 9.
    Alexanian R, Barlogie B, Tucker S (1990) VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 33:86–89PubMedCrossRefGoogle Scholar
  10. 10.
    Barlogie B, Smith L, Alexanian R (1984) Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353–1356PubMedGoogle Scholar
  11. 11.
    Samson D, Gaminara E, Newland A et al (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2:882–885PubMedCrossRefGoogle Scholar
  12. 12.
    Anderson H, Scarffe JH, Ranson M et al (1995) VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 71:326–330PubMedGoogle Scholar
  13. 13.
    Rajkumar SV, Blood E, Vesole D et al (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma; a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431–436PubMedCrossRefGoogle Scholar
  14. 14.
    Kumar S, Lacy MQ, Dispenzieri A et al (2004) Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 34:485–490PubMedCrossRefGoogle Scholar
  15. 15.
    Alexanian R, Dimopoulos MS, Delasalle et al (1992) Primary dexamethasone treatment of multiple myeloma. Blood 80:887–890PubMedGoogle Scholar
  16. 16.
    Huang SK, Mayhew E, Gilani S et al (1992) Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 52:6774–6781PubMedGoogle Scholar
  17. 17.
    Safra T, Muggia F, Jeffers S et al (2000) Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11:1029–1033PubMedCrossRefGoogle Scholar
  18. 18.
    Rifkin RM, Gregory SA, Mohrbacher A et al (2006) Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer 106:848–858PubMedCrossRefGoogle Scholar
  19. 19.
    McElwain TJ, Powles RL et al (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2:822–824PubMedCrossRefGoogle Scholar
  20. 20.
    Harousseau JL, Attal M, Divine M et al (1995). Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 85:3077–3085PubMedGoogle Scholar
  21. 21.
    Barlogie B, Kyle RA, Anderson KC et al (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24:929–936PubMedCrossRefGoogle Scholar
  22. 22.
    Blade J, Rosinol L, Sureda A et al (2005) High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106:3755–3759PubMedCrossRefGoogle Scholar
  23. 23.
    Fermand JP, Katsahian S, Divine M et al (2005) High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23:9227–9233PubMedCrossRefGoogle Scholar
  24. 24.
    Segeren CM, Sonneveld P, Van der Holt B et al (2003) Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101:2144–2151PubMedCrossRefGoogle Scholar
  25. 25.
    Attal M, Harousseau JL, Stoppa AM et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 11;335:91–97CrossRefGoogle Scholar
  26. 26.
    Child JA, Morgan GJ, Davies FE et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883PubMedCrossRefGoogle Scholar
  27. 27.
    Palumbo A, Bringhen S, Petrucci MT et al (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104:3052–3057PubMedCrossRefGoogle Scholar
  28. 28.
    Attal M, Harousseau JL, Facon T et al (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349:2495–2502PubMedCrossRefGoogle Scholar
  29. 29.
    Tohnya TM, Figg WD (2004) Immunomodulation of multiple myeloma. Cancer Biol Ther 3:1060–1061PubMedCrossRefGoogle Scholar
  30. 30.
    Glasmacher A, Hahn A, Hoffmann F et al (2005) A systematic review of phase II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Hematol 132:584–593CrossRefGoogle Scholar
  31. 31.
    Yakoub-Agha I, Doyen C, Hulin C et al (2006) A multicenter prospective randomized study testing non inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM 01-02 study. J Clin Oncol; ASCO Annual Meeting Proceedings Part I. [Supplements]:7520Google Scholar
  32. 32.
    Rajkumar SV, Hussein M, Catalano J et al (2006) A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma. Blood 108:238a (Abstract #795)CrossRefGoogle Scholar
  33. 33.
    Cavo M, Zamagni E, Tosi P et al (2005) Superiority of thalidomide and dexamethasone over vincristine doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35–39PubMedCrossRefGoogle Scholar
  34. 34.
    Macro M, Devine M, Uzunhan Y et al (2006) Dexamethasone + thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. Blood 108:22a (Abstract #57)Google Scholar
  35. 35.
    Zervas K, Mihou D, Katodritou E et al (2007) VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann Oncol 18:1369–1375PubMedCrossRefGoogle Scholar
  36. 36.
    Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomized controlled trial. Lancet 367:825–831PubMedCrossRefGoogle Scholar
  37. 37.
    Hulin C, Facon T, Rodon P et al (2007) Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥ 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Program and abstracts of the 49th Annual Meeting of the American Society of Hematology; Atlanta, Georgia. Abstract 75Google Scholar
  38. 38.
    Ludwig H, Tothova E, Hajek R et al (2007) Thalidomide-dexamethasone vs. melphalan-prednisone as first line treatment and thalidomide-interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma. Program and abstracts of the 49th Annual Meeting of the American Society of Hematology; Atlanta, Georgia. Abstract 529Google Scholar
  39. 39.
    Facon T, Mary J, Harousseau J et al (2006) Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J Clin Oncol 24:1s (Abstract #1)Google Scholar
  40. 40.
    Bartlett JB, Tozer A, Stirling D, et al (2005) Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 93:613–619PubMedCrossRefGoogle Scholar
  41. 41.
    Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063–3067PubMedCrossRefGoogle Scholar
  42. 42.
    Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood 96:2943–2950PubMedGoogle Scholar
  43. 43.
    Richardson P, Jagannath S, Schlossman R et al (2003) A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM) [abstract]. Blood 102:235a. Abstract 825Google Scholar
  44. 44.
    Rajkumar, Jacobus S, Callander N et al (2007) A randomized trial of lenalidomide plus high-dose dexamethasone (RD) vs. lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Program and abstracts of the 49th Annual Meeting of the American Society of Hematology; December 8–11, Atlanta, Georgia. Abstract 74Google Scholar
  45. 45.
    Anderson K, Richardson P, Chanan-Khan A et al (2006) Single-agent bortezomib in previously untreated multiple myeloma: results of a phase II multicenter study. J Clin Oncol 24:423s (Abstract 7504)Google Scholar
  46. 46.
    Chanan-Khan AA, Kaufman JL, Mehta J et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:2604–2606PubMedCrossRefGoogle Scholar
  47. 47.
    Richardson PG, Sonneveld P, Schuster M et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110:3557–3560PubMedCrossRefGoogle Scholar
  48. 48.
    Harousseau J-L, Attal M, Leleu X et al (2006) Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 91:1498–1505PubMedGoogle Scholar
  49. 49.
    Harousseau J-L, Marit G, Caillot D et al (2006) VELCADE/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenter phase III trial. Blood 108:21a (Abstract #56)Google Scholar
  50. 50.
    Oakervee HE, Popat R, Curry N et al (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 129:755–762PubMedCrossRefGoogle Scholar
  51. 51.
    Popat R, Oakervee H, Curry N et al (2007) Long term follow-up of PAD for untreated multiple myeloma. Haematologica 92[suppl 2]:181 (Abstract PO-725)Google Scholar
  52. 52.
    Orlowski RZ, Nagler A, Sonneveld P et al (2007) Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 25:3892–3901PubMedCrossRefGoogle Scholar
  53. 53.
    Cavo M, Patriarco F, Tacchetti P et al (2007) Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) vs. thalidomide-dexamethasone (TD) in preparation for autologous stem cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Program and abstracts of 49th Annual Meeting of the American Society of Hematology; Atlanta, Georgia. Abstract 73Google Scholar
  54. 54.
    San Miguel JF, Schlag R, Khuageva N et al (2007) MMY-3002: a phase 3 study comparing bortezomib melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Program and abstracts of the 49th Annual Meeting of the American Society of Hematology; Atlanta, Georgia. Abstract 76Google Scholar

Copyright information

© Springer-Verlag Italia 2008

Authors and Affiliations

  1. 1.Brown Cancer CenterUniversity of LouisvilleLouisvilleUSA

Personalised recommendations